ArticleBiotechnology letters2026
Biosynthesis of the fragrance compound cinnamyl isobutyrate in Escherichia coli.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Biosynthesis of the fragrance compound cinnamyl isobutyrate was achieved in Escherichia coli through acyltransferase selection and artificial pathway construction.The acyltransferase CATec3 Y20F responsible for cinnamyl isobutyrate formation was identified. Genes involved in cinnamyl alcohol biosynthesis, including Arabidopsis thaliana phenylalanine ammonia-lyase (AtPAL), Hypericum calycinum cinnamate:CoA ligase (HcCNL), Lolium perenne cinnamyl-CoA reductase (LpCCR1), and the branched-chain α-keto acid dehydrogenase complex (BKD) for isobutyryl-CoA biosynthesis, were introduced along with CATec3 Y20F into E. coli BL21 (DE3). The resulting recombinant strain, BD02, produced 2.6 mg/L cinnamyl isobutyrate and 428.9 mg/L cinnamyl acetate. Subsequently, alsS (encoding acetolactate synthase) from Bacillus subtilis and ilvC (encoding ketol-acid reductoisomerase)/ilvD (encoding dihydroxyacid dehydratase) from E. coli were overexpressed to increase the isobutyryl-CoA level, generating the recombinant strain BD03, which achieved a cinnamyl isobutyrate titer of 7.5 mg/L and 112.4 mg/L of cinnamyl acetate. Thereafter, the panB gene (encoding 3-methyl-2-oxobutanoate hydroxymethyltransferase), the pfkA gene (encoding phosphofructokinase), and the mdh gene (encoding malate dehydrogenase) were knocked out to enhance the supply of isobutyryl-CoA, resulting in the recombinant strain BD04. The strain BD04 produced 17.7 mg/L of cinnamyl isobutyrate and 67.2 mg/L of cinnamyl acetate. De novo biosynthesis of cinnamyl isobutyrate was achieved for the first time in engineered E. coli, thereby establishing a proof-of-concept for its microbial biosynthesis. This process was accompanied by the generation of cinnamyl acetate, which provides a reference for the microbial synthesis of diverse cinnamyl esters.
Indexed as
Identifiers
41524972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.